Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftigold is a generic antibiotic product developed and manufactured by the Vietnamese pharmaceutical company Fremed. It contains the active ingredient ceftriaxone, which is a third-generation cephalosporin. The drug functions by inhibiting bacterial cell wall synthesis through the binding and inhibition of penicillin-binding proteins (PBPs), which are enzymes involved in the final transpeptidation step of peptidoglycan synthesis. This leads to the weakening of the bacterial cell wall and eventual osmotic lysis. Ceftigold is indicated for the treatment of a wide range of bacterial infections, including lower respiratory tract infections, skin and skin structure infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, and meningitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ceftigold.